Monographie - Vinblastine sulfate

Dernière mise à jour :
19/11/2024

Vinblastine sulfate

Structure chimique

Noms commerciaux

Les noms commerciaux sont donnés à titre indicatif et la composition en excipients peut être différente selon les pays et selon les laboratoires

Blestinib	Mexique
Cytoblastin	Egypte, Malaisie
Lemblastine	Chili, Colombie, Mexique
Oncoblastin	Colombie
Uniblastin	Pérou
VBlastin	Inde
Velbe	Arabie Saoudite, Australie, Autriche, Chili, Danemark, Emirats Arabes Unis , Finlande, France, Grande Bretagne, Grèce, Italie, Luxembourg, Maroc, Norvège, Pays bas, Suède, Suisse
Velblastin	Egypte, Malaisie
Vinblasine	Luxembourg
Vinblastin	Hongrie, Pologne
Vinblastina	Argentine, Chili, Colombie, Equateur, Espagne, Mexique, Pérou, Roumanie
Vinblastine	Arabie Saoudite, Australie, Belgique, Canada, Etats Unis d’Amérique, France, Grande Bretagne, Iran, Irlande, Nouvelle Zélande, Pays bas, Tunisie
Vinblastinsulfat	Allemagne
Vinblatine	Malaisie
Vinko	Turquie

Bibliographie : Vinblastine sulfate

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
144	Revue	Dine T, Luyckx M, Cazin JC, Goudaliez F, Mallevais ML. Stability and compatibility studies of vinblastine, vincristine, vindesine and vinorelbine with PVC infusion bags. Int J Pharm 1991 ; 77: 279-285.
167	Revue	Francomb MM, Ford JL, Lee MG. Adsorption of vincristine, vinblastine, doxorubicin and mitoxantrone to in-line intravenous filters. Int J Pharm 1994 ; 103: 87-92.
169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
248	Revue	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	Revue	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
481	Revue	Beijnen JH, Vendrig DEMM, Underberg WJM. Stability of vinca alkaloid anticancer drugs in three commonly used infusion fluids. J Parenter Sci Technol 1989 ; 43: 84-87.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
763	Revue	Cohen MH, Jonhson-Early A, Hood MA, McKenzie M, Citron ML, Jaffe N, Krasnow SH. Drug precipitation within IV tubing : A potential hazard of chemotherapy administration. Cancer Treat Rep 1985 ; 69: 1325-1326.
827	Revue	Black J, Buechter DD, Thurston DE. Stability of vinblastine sulfate when exposed to light. Drug Intell Clin Pharm 1988 ; 22: 634-636.
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1009	Revue	Black J, Buechter DD, Chinn JW, Gard J, Thurston DE. Studies on the stability of vinblastine sulfate in aqueous solution. J Pharm Sci 1988 ; 77: 630-634.
1157	Revue	Vendrig DEMM, Smeets BPGM, Beijnen JH, van der Houwen OAGJ, Holthuis JJM. Degradation kinetics of vinblastine sulphate in aqueous solutions. Int J Pharm 1988 ; 43: 131-138.
1229	Revue	Weir PJ, Ireland DS. Chemical stability of cytarabine and vinblastine injections. Br J Pharm Pract 1990 ; 12: 53-54, 60.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1727	Revue	Mittner A, Vincze Z, Jemnitz K. Stability of vinblastine sulphate containing infusions. Pharmazie 1999 ; 54: 625-626.
1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
3540	Laboratoire	Heparin sodium - Summary of Product Characteristics. Wockhardt 2010
3578	Laboratoire	Cisplatin - Summary of Product Characteristics Accord Healthcare 2011
3644	Laboratoire	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010

Mentions Légales